Immunologic microenvironment and personalized treatment in multiple myeloma. - Wikidata - awgldk - TriplyDB

Immunologic microenvironment and personalized treatment in multiple myeloma.

Immunologic microenvironment and personalized treatment in multiple myeloma.

http://www.wikidata.org/entity/Q38108390

about

MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment MicroRNAs in multiple myeloma and related bone disease Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome.Immunological dysregulation in multiple myeloma microenvironment.Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.Mouse models of multiple myeloma: technologic platforms and perspectives.

P2860

Q26765477-E11727E9-13D0-4603-93EF-6B43B9EF1B0B Q26770478-22E6715A-7B00-410C-A346-917D14685A35 Q36545108-663E5FFA-4C05-4B4D-89F6-D17B31B3C260 Q38228353-7B689C34-4272-4101-A728-94B95B0C0E73 Q38299932-9AB9E264-1F13-4A98-953C-C91FCADE8A40 Q38526452-4A898F62-ACF1-4627-84E3-8801B00A37F5 Q38708402-D09B83DA-F7E1-403A-AFB4-3DA97C1F6702 Q38907104-C07C88C5-604F-452C-8430-670EA60BAD7A Q41091865-77541630-1DB6-46EC-B588-5EE74EA1B815 Q41894298-C75B09F3-D41C-48C2-B15D-42B5CD32401B Q47702288-559493DC-1BFB-417B-AF28-1BE9C62470E3 Q51735874-771C69DA-042D-43BE-8738-9F75B1474CEE Q55038802-9628A419-52AE-48CB-8628-CBE99D7B2CEA

P2860

Immunologic microenvironment and personalized treatment in multiple myeloma.

http://www.wikidata.org/entity/Q38108390

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunologic microenvironment and personalized treatment in multiple myeloma.

@en

type

label

Immunologic microenvironment and personalized treatment in multiple myeloma.

@en

prefLabel

Immunologic microenvironment and personalized treatment in multiple myeloma.

@en

P1433

Q38108390-BAEB360A-5B60-4889-873B-1325D653F6AD

P1476

Q38108390-E19E302C-4A5A-4913-9888-3CDE989519CA

P2093

Q38108390-7BD745C1-64C8-43B4-B7B7-042C84B6B133

Q38108390-CF942756-E746-479D-BABE-A1291C889331

P2860

Q38108390-01F8E6D8-BE1C-48E3-ABEA-F9693E41F915

Q38108390-07CEA786-7C23-483D-B669-A33477980D8D

Q38108390-0B0C11AA-EEB3-47CB-8E46-07BC7D56F6EE

Q38108390-0C5DAD72-047F-4A27-948E-9963433268C6

Q38108390-0F7D9969-E8DC-4817-8E2B-2B39E36F944E

Q38108390-0FC171F4-C628-4BDC-AF5D-5485BA430A0F

Q38108390-17B022B6-647E-4F71-83F5-D37DFCE60B38

Q38108390-1CE5DB40-2FC2-44BA-A985-4126CDAB2763

Q38108390-1EA74019-105D-4798-97E4-4DB9D8EC95BD

Q38108390-20F9E6D7-C898-4BE2-A133-203F1BE29226

P304

Q38108390-3A038CC9-297C-48DA-882A-4A78CE9376B6

P31

Q38108390-15B8D623-C3CD-45D0-8241-C0BD487E0FEC

P356

Q38108390-D907898A-67C7-486E-958C-F0679F8BF5A3

P407

Q38108390-1DC47201-51E8-4FAE-B440-3FAB33493B97

P478

Q38108390-6AAFC081-26F3-48CA-8531-FC55AD42B217

P50

Q38108390-C08B40AD-E410-4F07-87DD-62DAE4FC5584

Q38108390-F6F29FB5-B39E-4C8E-A64F-3D39A9B3A121

Q38108390-FFFDB73C-5EE8-4610-A9D2-89E4F740AF45

P577

Q38108390-A803D191-0218-4C53-ADE9-842245D47001

P698

Q38108390-F4895464-45FD-4C0B-AD47-D4F07D0B31E7

P356

14712598.2013.799130

P1433

Expert Opinion on Biological Therapy

P1476

Immunologic microenvironment and personalized treatment in multiple myeloma

@en

P2093

Pierfrancesco Tassone

http://www.w3.org/2001/XMLSchema#string

Pierosandro Tagliaferri

http://www.w3.org/2001/XMLSchema#string

P2860

Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Myeloid-derived suppressor cells as regulators of the immune system

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells

NK cell recognition

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

CTLA-4 control over Foxp3+ regulatory T cell function

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

P304

S83-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.799130

http://www.w3.org/2001/XMLSchema#string

P407

P478

13 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Pierpaolo Correale

P577

2013-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23692463

http://www.w3.org/2001/XMLSchema#string